On June 20th,Gelonghui announced that the company has received the "Drug Clinical Trial Approval Notice" for PZH2113 capsule new drug clinical trial approval. The company still needs to carry out clinical trials and undergo evaluation by the National Medical Products Administration before it can be marketed after approval. Zhangzhou Pientzehuang Pharmaceutical is the innovator for this new chemical drug product.

PZH2113 capsule is a first-class innovative chemical drug product with independent intellectual property rights developed by Zhangzhou Pientzehuang Pharmaceutical. It is mainly used for the treatment of relapsed/refractory non-Hodgkin's lymphoma, mainly diffuse large B-cell lymphoma. According to the relevant regulations of the new registration classification of chemical drugs, Zhangzhou Pientzehuang Pharmaceutical has completed pharmaceutical, pharmacology and toxicology, preclinical safety evaluation, and other research on raw materials and preparations for PZH2113 capsule. The research results show that PZH2113 capsule has good safety, drug formation, and clinical development value.